Gilead jumps further into cancer with $375mm Calistoga purchase
Gilead Sciences Inc. will pay $375mm cash to acquire privately held Calistoga Pharmaceuticals Inc. (cancer and inflammation therapies). Gilead has also agreed to pay up to an additional $225mm in earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.